-
Cart: 0 Items 0
My Cart
0 ItemsYour cart is empty
Subtotal :$0 USD
For years, men hesitated to start testosterone replacement therapy because of cardiovascular fears. The 2023 TRAVERSE trial began rewriting that story, and 2026 data has gone further. Here's what the evidence actually says — and how FYRE Body's medically supervised TRT protects your heart, not threatens it.
TRAVERSE (NEJM, 2023) randomized 5,246 men with hypogonadism and cardiovascular risk and found no increase in major adverse cardiac events versus placebo. This was the largest cardiovascular safety trial in TRT history.
Published in the World Journal of Men's Health (Imperial College London + Harvard BIDMC), this is the largest real-world TRT cohort ever. Findings: favorable safety, +1.26/5 libido improvement, all 8 quality-of-life domains significantly improved, and only modest hematocrit increases. 89% used subcutaneous testosterone; 7% used clomiphene citrate — validating the dual-pathway approach FYRE Body offers.
FDA experts continue to push for removing prostate cancer warnings from TRT labeling. The Endocrine Society's 2026 annual meeting linked TRT to weight loss and metabolic syndrome improvement — both major cardiovascular protective factors.
Also see: FYRE Body blog for our deep dives on TRT timeline, sleep, and weight loss.
The TRAVERSE trial and the 9,537-man cohort both show no increased MACE risk in monitored patients.
Both options have favorable cardiovascular profiles when monitored. Enclomiphene preserves natural production and has a milder hematocrit effect.
Standard testosterone panel, CBC (for hematocrit), PSA, estradiol, and metabolic panel.